Immunitybio Stock Fundamentals
| IBRX Stock | USD 2.75 0.04 1.48% |
Immunitybio fundamentals help investors to digest information that contributes to Immunitybio's financial success or failures. It also enables traders to predict the movement of Immunitybio Stock. The fundamental analysis module provides a way to measure Immunitybio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunitybio stock.
At this time, Immunitybio's Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 15.5 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 12.5 M in 2025.
Immunitybio | Select Account or Indicator |
Immunitybio Company Current Valuation Analysis
Immunitybio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunitybio Current Valuation | 2.79 B |
Most of Immunitybio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunitybio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immunitybio Current Valuation Historical Pattern
Today, most investors in Immunitybio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunitybio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunitybio current valuation as a starting point in their analysis.
Immunitybio Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunitybio has a Current Valuation of 2.79 B. This is 80.6% lower than that of the Biotechnology sector and 40.01% lower than that of the Health Care industry. The current valuation for all United States stocks is 83.24% higher than that of the company.
Immunitybio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunitybio's current stock value. Our valuation model uses many indicators to compare Immunitybio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunitybio competition to find correlations between indicators driving Immunitybio's intrinsic value. More Info.Immunitybio is rated below average in return on asset category among its peers. It is rated below average in operating margin category among its peers . At this time, Immunitybio's Operating Profit Margin is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunitybio's earnings, one of the primary drivers of an investment's value.Immunitybio Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunitybio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics of similar companies.Immunitybio is currently under evaluation in current valuation category among its peers.
Immunitybio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunitybio from analyzing Immunitybio's financial statements. These drivers represent accounts that assess Immunitybio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunitybio's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 5.1B | 2.4B | 2.0B | 2.6B | 2.9B | 2.7B | |
| Enterprise Value | 5.3B | 2.8B | 2.6B | 3.0B | 3.5B | 2.8B |
Immunitybio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunitybio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunitybio's managers, analysts, and investors.Environmental | Governance | Social |
Immunitybio Fundamentals
| Return On Asset | -0.48 | ||||
| Operating Margin | (9.19) % | ||||
| Current Valuation | 2.79 B | ||||
| Shares Outstanding | 853.44 M | ||||
| Shares Owned By Insiders | 62.90 % | ||||
| Shares Owned By Institutions | 9.87 % | ||||
| Number Of Shares Shorted | 56.96 M | ||||
| Price To Sales | 164.96 X | ||||
| Revenue | 14.74 M | ||||
| Gross Profit | 14.74 M | ||||
| EBITDA | (264.43 M) | ||||
| Net Income | (413.64 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 42.29 M | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.57) X | ||||
| Cash Flow From Operations | (391.24 M) | ||||
| Short Ratio | 9.95 X | ||||
| Earnings Per Share | (0.62) X | ||||
| Price To Earnings To Growth | 3.69 X | ||||
| Target Price | 11.25 | ||||
| Number Of Employees | 680 | ||||
| Beta | -0.18 | ||||
| Market Capitalization | 2.43 B | ||||
| Total Asset | 382.93 M | ||||
| Retained Earnings | (3.38 B) | ||||
| Working Capital | 129.64 M | ||||
| Net Asset | 382.93 M |
About Immunitybio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 90 K | 85.5 K | |
| Total Revenue | 14.7 M | 15.5 M | |
| Stock Based Compensation To Revenue | 2.34 | 2.22 | |
| Sales General And Administrative To Revenue | 543.71 | 802.07 | |
| Research And Ddevelopement To Revenue | 12.90 | 12.25 | |
| Capex To Revenue | 0.47 | 0.44 | |
| Revenue Per Share | 0.02 | 0.02 | |
| Ebit Per Revenue | (23.34) | (24.51) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.